Menu
Sign In Search Podcasts Charts People & Topics Add Podcast API Blog Pricing
Podcast Image

WSJ Minute Briefing

Iran Dismisses U.S. Peace Plan

25 Mar 2026

Transcription

Chapter 1: What is the main topic discussed in this episode?

3.052 - 8.578 Alex Ossola

Here's your midday brief for Wednesday, March 25th. I'm Alex Osola for The Wall Street Journal.

0

9.919 - 18.408 Unknown

Iran has dismissed the Trump administration's 15-point plan to end the war and says it amounts to a wish list of objectives that haven't been achieved militarily.

0

19.009 - 38.112 Alex Ossola

Iran set out its own conditions for a ceasefire via a state broadcaster, including an end to attacks by the U.S. and Israel, financial compensation for damages caused by the conflict, and sovereignty over the Strait of Hormuz. President Trump has installed some of the biggest names in business to a technology council to weigh in on AI policy and other issues.

0

38.594 - 57.945 Alex Ossola

Some of those names include Meta CEO Mark Zuckerberg, Oracle Executive Chairman Larry Ellison, and NVIDIA CEO Jensen Wang. And Merck has agreed to a nearly $6 billion cash deal to acquire the California biotech firm Turns Pharmaceutical to gain access to a promising experimental pill for chronic myeloid leukemia.

0

58.386 - 65.373 Alex Ossola

Merck's top-selling drug, Keytruda, is losing patent protection in 2028, which could mean a big chunk of lost revenue for Merck.

Chapter 2: What are Iran's conditions for a ceasefire according to their response to the U.S. peace plan?

66.013 - 85.419 Alex Ossola

Analysts say the new leukemia treatment could become a blockbuster, with more than $2 billion in annual sales. Heads up, an artificial intelligence tool helped us make this episode by creating summaries that were based on WSJ reporting and then reviewed and adapted by an editor. We'll have more coverage of the day's news on the WSJ's What's News podcast.

0

85.639 - 91.497 Alex Ossola

You can add it to your playlist on your smart speaker or listen and subscribe wherever you get your podcasts.

0
Comments

There are no comments yet.

Please log in to write the first comment.